UNITY is harnessing pathways of aging biology to develop new medicines, with a focus on retinal diseases. Independence. At UNITY we are advancing the first senolytic therapeutic for retinal …

Unity Biotechnology, Inc. is a publicly traded American biotechnology company that develops drugs that target senescent cells. [1][2][3][4][5] Unity BioTechnologies, a company backed by …

We aspire to develop transformative medicines by leveraging fundamental pathways of aging biology, with a focus in retinal diseases. Working at the frontier of biotechnology and medicine, …

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.

We are developing therapeutics that target senescence and adjacent biology with established endpoints and well-defined regulatory pathways to approval. Our initial focus is on delivering …

针对这一问题，初创企业 Unity Biotechnology 将目光聚焦细胞衰老领域，致力于研发抗衰老治疗药物。 今天，Unity Biotechnology 宣布获得 1.16 亿美元 B 轮融资，由亚马逊 CEO Jeff Bezos …

UNITY is harnessing pathways of aging biology to develop new medicines, with a focus on retinal diseases. As pioneers in cellular senescence, UNITY is advancing the first senolytic...

2024年2月6日 · UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or …

Get the latest Unity Biotechnology, Inc. (UBX) stock news and headlines to help you in your trading and investing decisions.

2021年5月11日 · SOUTH SAN FRANCISCO, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing …